Literature DB >> 7963735

Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment.

S E Malawista1, S W Barthold, D H Persing.   

Abstract

Persistence of Borrelia burgdorferi DNA in tissues following antibiotic treatment was evaluated in C3H mice inoculated intradermally with 10(3) B. burgdorferi N40 or sterile medium. Half of the infected mice and all of the uninfected mice were treated with ceftriaxone 15 days after inoculation for 5 days. Ear and urinary bladder samples were collected on days 20, 30, and 60 after inoculation for culture and for extraction of DNA and amplification of specific spirochetal DNA by polymerase chain reaction (PCR). PCR primers were specific for a 280-bp portion of a highly conserved region of the gene encoding outer surface protein (Osp) A of B. burgdorferi and for a 328-bp part of the OspB gene. There was excellent concordance between culture and PCR for ears (35/36 mice) and bladders (33/36). Both tissues became uniformly negative at the earliest interval tested after antibiotic treatment. Thus, the ability to amplify B. burgdorferi DNA quickly disappeared from tissues that had become culture-negative after antibiotic treatment, suggesting that serial study of PCR-positive tissues and fluids may be useful for evaluating the efficacy of antibiotic therapy in human Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963735     DOI: 10.1093/infdis/170.5.1312

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis.

Authors:  Clarisse Rovery; Gilbert Greub; Hubert Lepidi; Jean-Paul Casalta; Gilbert Habib; Frédéric Collart; Didier Raoult
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 2.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

Review 3.  Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates.

Authors:  D N Fredricks; D A Relman
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

4.  Comparison of urinary bladder and ear biopsy samples for determining prevalence of Borrelia burgdorferi in rodents in central Europe.

Authors:  T N Petney; D Hassler; M Brückner; M Maiwald
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

5.  Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms. A PCR study of 97 cases.

Authors:  M E Bayer; L Zhang; M H Bayer
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

6.  The Lyme disease agent exploits a tick protein to infect the mammalian host.

Authors:  Nandhini Ramamoorthi; Sukanya Narasimhan; Utpal Pal; Fukai Bao; Xiaofeng F Yang; Durland Fish; Juan Anguita; Michael V Norgard; Fred S Kantor; John F Anderson; Raymond A Koski; Erol Fikrig
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

7.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

8.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 9.  Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

10.  Nitric oxide production during murine Lyme disease: lack of involvement in host resistance or pathology.

Authors:  K P Seiler; Z Vavrin; E Eichwald; J B Hibbs; J J Weis
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.